Economic news

AstraZeneca Shares Sink 8% after $39 Billion Alexion Buyout

Dec 14 (Reuters) - Shares of AstraZeneca fell 8% early on Monday, hit by doubts about the British firm’s strategy and speculation of a rival bid after it announced the $39 billion purchase of Alexion Pharmaceuticals over the weekend.

Chief Executive Officer Pascal Soriot had told reporters on Saturday that the deal, a bet on rare-disease and immunology drugs, was the result of exclusive talks and no competitive bidder was involved.

The move also helps AstraZeneca, which is also working on a COVID-19 vaccine, diversify from its fast-growing cancer business.

(Reporting by Pushkala Aripaka in Bengaluru; Editing by Arun Koyyur)

Source: Reuters

To leave a comment you must or Join us

More news

Back to economic news list

By visiting our website and services, you agree to the conditions of use of cookies. Learn more
I agree